International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1520-1525

  Grant, Philip M ^a   Taylor, Jonathan ^a   Nevins, Andrew B ^a   Calvez, Vincent ^b   Marcelin, Anne Geneviève ^b   Wirden, Marc ^b   Zolopa, Andrew R ^a  

^a STANFORD UNIVERSITY   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMIDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TOLERABILITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CALIFORNIA; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FRANCE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PHOSPHONIC ACIDS; RNA, VIRAL; ZIDOVUDINE;

EID: 77950173484     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01380-09     Document Type: Article

References (30)

1. Antinori, A., M. P. Trotta, P. Lorenzini, C. Torti, N. Gianotti, F. Maggiolo, F. Ceccherini-Silberstein, P. Nasto, A. Castagna, A. De Luca, C. Mussini, M. Andreoni, C. F. Perno, and the GNOMO Study Group. 2007. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antivir. Ther. 12:1175-1183.
2. Boucher, S., P. Recordon-Pinson, J. M. Ragnaud, M. Dupon, H. Fleury, and B. Masquelier. 2006. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med. 7:294-298.
3. Campbell, T. B., N. S. Shulman, S. C. Johnson, A. R. Zolopa, R. K. Young, L. Bushman, C. V. Fletcher, E. R. Lanier, T. C. Merigan, and D. R. Kuritzkes. 2005. Antiviral activity of lamivudine in salvage therapy for multidrugresistant HIV-1 infection. Clin. Infect. Dis. 41:236-242.
4. Castagna, A., A. Danise, S. Menzo, L. Galli, N. Gianotti, E. Carini, E. Boeri, A. Galli, M. Cernuschi, H. Hasson, M. Clementi, and A. Lazzarin. 2006. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20:795-803.
5. Craig, C., and G. J. Moyle. 1997. The development of resistance of HIV-1 to zalcitabine. AIDS 11:271-279.
6. Deeks, S., R. Hoh, T. Neilands, T. Liegler, F. Aweeka, C. J. Petropoulos, R. M. Grant, and J. N. Martin. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537-1544.
7. de Mendoza, C., C. Garrido, A. Corral, G. Ramírez-Olivencia, I. Jiménez-Nacher, N. Zahonero, J. Gonzalez-Lahoz, and V. Soriano. 2007. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res. Hum. Retroviruses 23:879-885.
8. de Mendoza, C., I. Jimenez-Nacher, C. Garrido, P. Barreiro, E. Poveda, A. Corral, N. Zahonero, J. González-Lahoz, and V. Soriano. 2008. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. Clin. Infect. Dis. 46:1782-1785.
9. Doualla-Bell, F., A. Avalos, B. Brenner, T. Gaolathe, M. Mine, S. Gaseitsiwe, M. Oliveira, D. Moisi, N. Ndwapi, H. Moffat, M. Essex, and M. A. Wainberg. 2006. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 50:4182-4185.
10. Efron, B., and R. Tibshirani. 1993. Introduction to the bootstrap. Chapman & Hall/CRC Press, Boca Raton, FL.
11. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333:1662-1669.
12. Forum for Collaborative HIV Research. 26 April 2009, accession date. Standardization and clinical relevance of HIV drug resistance testing. Forum for Collaborative HIV Research, Washington, DC. http://www.hivforum.org /projets/standardization.html.
13. Frankel, F. A., C. F. Invernizzi, M. Oliveira, and M. A. Wainberg. 2007. Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 21:665-675.
14. Gallant, J., E. DeJesus, J. Arribas, A. L. Pozniak, B. Gazzard, R. E. Campo, B. Lu, D. McColl, S. Chuck, J. Enejosa, J. J. Toole, A. K. Cheng, and the 934 Study Group. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354:251-260.
15. Gallant, J., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, A. K. Cheng, and the 903 Study Group. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA 292:191-201.
16. Hosseinipour, M., J. Kumwenda, R. Weigel, L. Brown, D. Mzinganjira, B. Mhango, S. Phiri, and J. Van Oosterhout. 2009. Clinical, immunological, and virological outcomes of second-line treatment, Malawi, abstr. 605. Abstr. 16th Conf. Retroviruses Opportun. Infect.
17. Kuritzkes, D. R., J. B. Quinn, S. L. Benoit, D. L. Shugarts, A. Griffin, M. Bakhtiari, D. Poticha, J. J. Eron, M. A. Fallon, and M. Rubin. 1996. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10:975-981.
18. Louie, M., C. Hogan, A. Hurley, V. Simon, C. Chung, N. Padte, P. Lamy, J. Flaherty, D. Coakley, M. Di Mascio, A. S. Perelson, and M. Markowitz. 2003. Determining the antiviral activity of tenofovir disoproxil fumarate in treatmentnaive chronically HIV-1-infected individuals. AIDS 17:1151-1156.
19. Margot, N. A., E. Isaacson, I. McGowan, A. K. Cheng, R. T. Schooley, and M. D. Miller. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227-1235.
20. McColl, D. J., C. Chappey, N. T. Parkin, and M. D. Miller. 2008. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir. Ther. 13:189-197.
21. McColl, D. J., N. A. Margot, M. Wulfsohn, D. F. Coakley, A. K. Cheng, and M. D. Miller. 2004. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J. Acquir. Immune Defic. Syndr. 37:1340-1350.
22. Parikh, U. M., D. C. Barnas, H. Faruki, and J. W. Mellors. 2006. Antagonism between the HIV-1 reverse transcriptase mutation K65R and thymidine analogue mutations at the genomic level. J. Infect. Dis. 194:651-660.
23. Pillay, V., C. Pillay, R. Kantor, F. Venter, L. Levin, and L. Morris. 2008. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 24:1449-1454.
24. Shen, L., S. Peterson, A. R. Sedaghat, M. A. McMahon, M. Callender, H. Zhang, Y. Zhou, E. Pitt, K. S. Anderson, E. P. Acosta, and R. F. Siliciano. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766.
25. Sungkanuparph, S., W. Manosuthi, S. Kiertiburanakul, N. Saekang, W. Pairoj, and W. Chantratita. 2008. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J. Clin. Virol. 41:310-313.
26. Weber, J., B. Chakraborty, J. Weberova, M. D. Miller, and M. E. Quiñones-Mateu. 2005. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol. 43:1395-1400.
27. White, K. L., J. M. Chen, J. Y. Feng, N. A. Margot, J. K. Ly, A. S. Ray, H. L. Macarthur, M. J. McDermott, S. Swaminathan, and M. D. Miller. 2006. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther. 11:155-163.
28. World Health Organization. 21 April 2009, accession date. Antiretroviral treatment guidelines for HIV-1 infected adults and adolescents. World Health Organization, Geneva, Switzerland. www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf.
29. World Health Organization. 29 December 2009, accession date. Rapid advice antiretroviral therapy for HIV infection in adults and adolescents. Available at: World Health Organization, Geneva, Switzerland. www.who.int/hiv/pub/arv/rapid-advice-art.pdf.
30. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.